
Positive results from STEP-HFpEF indicate that semaglutide can improve quality of life and functional capacity in patients with obesity-related heart failure with preserved ejection fraction (HFpEF), but large outcomes trials are needed to confirm this, said Javed Butler, MD, MPH, MBA.


























